arrow
S

Sergey Orlov

Pavlov First Saint Petersburg State Medical University
H指数:26
被引数:5,479

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Central nervous system outcomes of lazertinib treatment in EGFR-mutated advanced NSCLC: Pooled analysis from LASER201 and LASER301

拉泽替尼治疗EGFR突变晚期NSCLC的神经系统结局:LASER201和LASER301的合并分析

2025-09-010
PREAI
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study

奥希替尼在参加AURA计划或FLAURA研究的EGFRm NSCLC患者中的长期耐受性

2025-01-010
PRE
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer

卡马替尼在MET外显子14突变或MET扩增的非小细胞肺癌中的应用

2020-09-03635
OAAI
Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)
2020-08-152
PRE
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
2020-01-0113
OAAI
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
2019-10-24983
OAAI
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

FGF配体阱GSK3052230联合培美曲塞和顺铂治疗恶性胸膜间皮瘤的Ib期研究

2019-05-0721
OAAI